Overview

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Status:
Not yet recruiting

Trial end date:
2024-09-30

Target enrollment:

Participant gender:

Summary

AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Affimed GmbH

Treatments:

Atezolizumab